Aureka Biotechnologies
Latest round
- Series B
Last raised
- Oct 2026
Total raised
- $235M
Investors
- 9
About Aureka Biotechnologies
trading under the name Aureka, was founded to provide drug discovery services for complex targets in the pharmaceutical industry. The company was co-founded by Dr. Weian Zhao (CEO), Alon Wellner and Shuangjia Zheng with a core team focused on integrating microfluidic systems, synthetic biology, and artificial intelligence. Since its inception, the firm has advanced from platform development to large-scale molecular design and has established partnerships with several multinational pharmaceutical companies. The company works with multinational pharmaceutical and biotechnology firms to provide its proprietary AuraIDE™ intelligent antibody design platform. Its technology solutions leverage high-throughput microfluidic systems to characterize complex drug functions, such as agonistic activity, endocytosis, and brain permeability, delivering commercial-ready pipeline data packages (including pre-CMC and pre-toxicology data) within 9 to 12 months. The company’s internal pipeline focuses on antibody drug development for cardiovascular, metabolic, immunological, and central nervous system diseases. The company generates revenue from B2B business development transactions and project collaborations with pharmaceutical and biotechnology companies. This includes fees for the delivery of differentiated functional molecules designed by AI agents and the provision of comprehensive drug pipeline data packages.
Who invested in Aureka Biotechnologies
9 investors across 5 rounds
See all investors in Aureka Biotechnologies
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Aureka Biotechnologies
Who invested in Aureka Biotechnologies?
Aureka Biotechnologies has 9 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Aureka Biotechnologies raised?
Aureka Biotechnologies has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Aureka Biotechnologies last raise money?
Aureka Biotechnologies's most recent round on record is a Series B, in Oct 2026.
What does Aureka Biotechnologies do?
trading under the name Aureka, was founded to provide drug discovery services for complex targets in the pharmaceutical industry.
Where is Aureka Biotechnologies headquartered?
Aureka Biotechnologies is headquartered in Laguna Hills, US.
Which VCs invest in companies like Aureka Biotechnologies?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Aureka Biotechnologies's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Aureka Biotechnologies? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.